EpiBiologics
Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...
$107MSeries B
Role not disclosedActivity from announced rounds
Develops novel bispecific antibodies for targeted degradation of extracellular proteins in oncolo...